NR 293 RUA
Student Name
Chamberlain University
NR-293: Pharmacology for Nursing Practice
Prof. Name
Date
Medication Teaching Plan
Overview of Xtampza ER (Oxycodone)
Xtampza ER is an extended-release formulation of oxycodone, a potent opioid analgesic classified as a Schedule II controlled substance under the United States Controlled Substances Act. Oxycodone belongs to the narcotic (opioid) drug class and is primarily indicated for managing moderate to severe pain that requires continuous, around-the-clock opioid therapy when alternative treatment options are inadequate.
The drug exerts its effects by binding to mu-opioid receptors within the central nervous system (CNS), altering the perception of pain and producing generalized CNS depression (Vallerand, Sanoski, & Quiring, 2019). This mechanism not only reduces pain intensity but may also influence emotional responses to pain.
Target Audience
This educational brochure is designed for patients prescribed Xtampza ER, as well as their caregivers. While most patients are adults experiencing chronic pain, pediatric patients may also receive oxycodone at carefully adjusted doses — typically 0.05–0.15 mg/kg every 4–6 hours as needed — under strict medical supervision (Vallerand et al., 2019).
The brochure serves as a comprehensive, patient-friendly resource containing key information such as:
- Drug classification
- Mechanism of action
- Administration and dosage guidelines
- Drug–drug interactions
- Laboratory effects and potential interferences
- Special considerations
- Adverse effects and toxicity warnings
- Patient assessment criteria
- Essential patient teaching points
Special Considerations
Xtampza ER carries significant risks due to its high abuse potential. Misuse can lead to addiction, overdose, and potentially fatal respiratory depression. Patients must be informed about safe storage, theft prevention, and the dangers of sharing their medication. The medication should be kept out of sight and reach of children and stored in a secure, inaccessible location.
In addition, oxycodone use during pregnancy may result in neonatal opioid withdrawal syndrome and can cause fetal harm. Pregnant patients should avoid this medication unless absolutely necessary, and prescribers should discuss safer alternatives (Collegium Pharmaceutical, 2023).
Patient Teaching Considerations
Proper patient education plays a critical role in promoting safe and effective use of Xtampza ER. Healthcare providers should ensure patients understand:
NR 293 RUA
| Teaching Point | Key Information |
|---|---|
| Dosage & Timing | Take exactly as prescribed, at the same times each day. Do not crush or chew capsules, as this can cause rapid release and absorption of a potentially fatal dose. |
| Route of Administration | Oral; swallow capsules whole or sprinkle contents on soft food if necessary, following specific instructions. |
| Missed Dose | Take the missed dose as soon as remembered unless it is near the time for the next scheduled dose. Do not double doses. |
| Storage | Keep in a locked location, away from children and unauthorized individuals. |
| Signs of Overdose | Recognize symptoms such as extreme sleepiness, slowed breathing, or loss of consciousness; seek emergency medical help immediately. |
| Abuse Prevention | Never share with others. Dispose of unused medication via take-back programs. |
| Pregnancy Warning | Avoid during pregnancy due to potential harm to the fetus. |
| Drug Interactions | Avoid alcohol, sedatives, and other CNS depressants unless approved by a healthcare provider. |
Mechanism of Action and Effects
Oxycodone works by binding to opioid receptors in the CNS, particularly mu-receptors, thereby reducing the brain’s perception of pain and altering the emotional response to discomfort. While effective, this mechanism also causes CNS depression, which can manifest as sedation, slowed breathing, and, in severe cases, coma or death.
Therapeutically, the primary goal is to achieve effective pain control while minimizing the risk of adverse events.
Key Safety Messages for Patients
- Understand the Risk of Dependence – Patients should be aware that oxycodone can cause physical and psychological dependence.
- Avoid Abrupt Discontinuation – Stopping the medication suddenly after long-term use may cause withdrawal symptoms; tapering should be medically supervised.
- Report Side Effects Promptly – Common side effects include constipation, nausea, dizziness, and drowsiness. Severe effects like respiratory depression require immediate medical attention.
- Follow Prescriber’s Instructions Strictly – Self-adjusting the dose can be dangerous.
References
Collegium Pharmaceutical, Inc. (2023). Xtampza ER (oxycodone) extended-release capsules [Prescribing information]. U.S. Food and Drug Administration. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b0a5ded2-8ee2-49ca-a86c-2b28ae40f60c
NR 293 RUA
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2019). Davis’s drug guide for nurses (17th ed.). F. A. Davis Company.